纳米载药系统调控肿瘤相关巨噬细胞抗肿瘤研究进展

韦朝晗,丁梓荞,张晓琼,雍土莹,甘璐,杨祥良

Research Progress on Nano Drug Delivery System Regulating Tumor-associated Macrophages for Cancer Therapy

Zhaohan WEI,Ziqiao DING,Xiaoqiong ZHANG,Tuying YONG,Lu GAN,Xiangliang YANG

图4 纳米药物靶向阻断CD47-SIRPα信号通路增强TAMs吞噬能力 M1 Exo-Ab(A)[60]、aPD1@aCD47 complex(B)[61]、SNPACALR&aCD47(C)[62]阻断肿瘤细胞与巨噬细胞的 CD47-SIRPα 信号通路,增强巨噬细胞对肿瘤的吞噬,提高抗肿瘤效果。

Fig.4 Nanomedicines enhance macrophage phagocytosis of TAMs by targeted blocking of CD47-SIRPα signaling pathway M1 Exo-Ab (A)[60],aPD1@aCD47 complex (B)[61] and SNPACALR&aCD47 (C)[62] disrupt CD47-SIRPα signaling pathway between tumor cells and TAMs,improve macrophage-mediated phagocytosis of tumor and antitumor effects.